The Senate has approved Trump’s most controversial picks, including Tulsi Gabbard and RFK Jr. Here’s the full list and ...

We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Trump chose two tech figures – Elon Musk and Vivek Ramaswamy – to lead a cost-cutting effort dubbed the "Department of ...

Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...

We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Cantor Fitzgerald has a “Neutral” rating and a $110.00 price objective on the stock. The consensus estimate for Fortinet’s current full-year earnings is $2.05 per share. Get Fortinet alerts: ...

Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for AST SpaceMobile’s current full-year earnings is ($0.40) per share ...

Cantor Fitzgerald raised concerns about the Magnificent Seven stocks, suggesting they may be at risk of losing investor interest as fund flows shift to other sectors. Revenue projections for 2025 are ...

Cantor Fitzgerald upgraded CVS Health (CVS) to Overweight from Neutral. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data ...

In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Proto Labs (PRLB – Research Report), with a price target of $50.00. The company’s shares closed ...